Recombinant Human CD300b/LMIR5 Fc Chimera Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

LMIR5, also known as CD300b, CD300LB, CLM-7, and IREM‑3, is a glycoprotein member of the immunoglobulin superfamily (1). Human LMIR5 consists of a 134 amino acid (aa) extracellular domain (ECD) with one Ig-like V-type domain, a 21 amino acid (aa) transmembrane segment, and a 29 aa cytoplasmic domain (2). Within the ECD, human LMIR5 shares 51 % sequence identity with mouse and 57% aa sequence identity with rat LMIR5. The transmembrane segment contains a positively charged lysine which enables the association of LMIR5 with DAP12, DAP10, and potentially other adaptor proteins (2, 3). The cytoplasmic domain of human LMIR5 contains a phosphorylatable tyrosine motif, while that of mouse LMIR5 does not (2). LMIR5 is expressed on the surface of myeloid lineage cells (2-4). It forms noncovalent cis‑homodimers and cis-heterodimers with other CD300 family proteins, and the composition of these dimers affects the cellular response (2, 5). Antibody cross‑linking of LMIR5 induces mast cell granule release and cytokine production as well as its tyrosine phosphorylation of LMIR5 (in human) (2, 3). LMIR5 interacts with TIM1 and TIM4 which regulate T cell activation and are themselves binding partners (6). TIM1 interactions with LMIR5 mediate mast cell activation and the accumulation of neutrophils at sites of TIM1 up‑regulation on damaged renal tubule epithelial cells (6).

Array 1522-LM

• CD300b/LMIR5/CD300LB Antibodies
• CD300b/LMIR5/CD300LB Lysate
• CD300b/LMIR5/CD300LB Protein
• CD300b/LMIR5/CD300LB Proteins and Enzymes